Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis

Parfieniuk, 2007, Specifically targeted antiviral therapy for hepatitis C virus, World J Gastroenterol, 21, 5673, 10.3748/wjg.v13.i43.5673 Breban, 2013, Towards realistic estimates of HCV incidence in Egypt, J Viral Hepat, 20, 294, 10.1111/j.1365-2893.2012.01650.x Abdel-Aty, 2017, Incidence of HCV induced-esophageal varices in Egypt: valuable knowledge using data mining analysis, Medicine (Baltimore), 96, e5647, 10.1097/MD.0000000000005647 Asselah, 2012, Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow, Liver Int, 32, 88, 10.1111/j.1478-3231.2011.02699.x Koff, 2014, The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection, Aliment Pharmacol Ther, 39, 478, 10.1111/apt.12601 Kirby, 2015, Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir, Clin Pharmacokinet, 54, 677, 10.1007/s40262-015-0261-7 Bernuth, 2016, Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir, Dig Liver Dis, 48, 291, 10.1016/j.dld.2015.09.015 Fontana, 2016, Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection, Liver Transpl, 22, 446, 10.1002/lt.24416 Asselah, 2014, Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy, J Hepatol, 61, 435, 10.1016/j.jhep.2014.04.042 Sulkowski, 2014, Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N Engl J Med, 16, 211, 10.1056/NEJMoa1306218 Kamal, 2014, Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents, Hepatic Med, 6, 61, 10.2147/HMER.S41127 Santos, 2015, Analysis of polymorphism in the interleukin 18 gene promotor (-137 G/C and -607 C/A) in patients infected with hepatitis c virus from the Brazilian Amazon, Arq Gastroenterol, 52, 222, 10.1590/S0004-28032015000300013 Sterling, 2005, Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection, Hepatology, 43, 1317, 10.1002/hep.21178 Zhang, 2010, Value of FIB-4 for the diagnosis of liver fibrosis in chronic hepatitis B, Zhonghua Shi Yan He Lin Chuang Bing Du Xue ZaZhi, 24, 215 European Association for Study of Liver, 2015, EASL recommendations on treatment of hepatitis C 2015, J Hepatol, 63, 199, 10.1016/j.jhep.2015.03.025 Medrano, 1990, DNA extraction from nucleated red blood cells, Biotechniques, 8, 43 An, 2008, Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance, J Infect Dis, 198, 1159, 10.1086/592047 Hezode, 2015, Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (command-4), Antivir Ther, 21, 195, 10.3851/IMP2985 Murakami, 2014, Ultra deep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin, Antimicrob Agents Chemother, 58, 2105, 10.1128/AAC.02068-13 Stedman, 2014, Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential, Therap Adv Gastroenterol, 7, 131, 10.1177/1756283X13515825 Poordad, 2016, Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence, Hepatology, 63, 1493, 10.1002/hep.28446 Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 Guarino, 2017, Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis, Aliment Pharmacol Ther, 45, 1193, 10.1111/apt.14017 Wu, 2016, Modeling ribavirin-induced anemia in patients with chronic hepatitis C virus, CPT Pharmacometr Syst Pharmacol, 5, 65, 10.1002/psp4.12058 Dyson, 2016, Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use, J Hepatol, 64, 234, 10.1016/j.jhep.2015.07.041 Lee, 2013, Daclatasvir potential role in hepatitis C, Drug Des Dev Ther, 7, 1223, 10.2147/DDDT.S40310 University of Liverpool Hepatitis Drug Interactions. Website: https://www.liverpool.ac.uk/www.hep_druginteractions.org. Accessed October 2016. Soriano, 2015, Drug interactions with new hepatitis C oral drugs, Expert Opin Drug Metab Toxicol, 11, 333, 10.1517/17425255.2015.998997 Haas, 2009, Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response, J Clin Immunol, 29, 620, 10.1007/s10875-009-9302-z Yang, 2015, Association between interleukin-18 gene promoter (−607C/A and −137G/C) polymorphisms and chronic hepatitis C virus infections: a meta-analysis, Meta Gene, 5, 21, 10.1016/j.mgene.2015.04.004 Abdelraheem, 2016, Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin, Arch Virol, 161, 2473, 10.1007/s00705-016-2948-y